ResApp to speed up tests

Digital medicine developer ResApp Health has announced its second clinical trial program in Perth as it seeks to accelerate the testing of its smartphone-based diagnosis of respiratory disease.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 28/02/18

1 year TSR5 year TSR
624thDepartment 13 International-32%-15%
625thEphraim Resources-32%-15%
761stResApp Health-60%85%
711 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$65k Bought
$49k Bought
$49k Other
Total value as at the date of the transaction
Source: Morningstar


143rd-MOKO Social Media$1.2m
144th↑ResApp Health$1.1m
145th↑Department 13 International$1.1m
146th↑Ephraim Resources$1.1m
236 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from ResApp Health

211thTony Keating$537k
1110thBrian Leedman$78k
365thRoger Aston$72k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer